- Home
- APRE vs SEGG Comparison
APRE vs SEGG Comparison
Compare APRE & SEGG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APRE | SEGG |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 11.6M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | APRE | SEGG |
|---|---|---|
| Price | $0.75 | $2.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.10 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 220.9K | 40.1K |
| Earning Date | 05-13-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.22 | ★ 70.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,779,057.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $0.42 |
| 52 Week High | $1.69 | $5.11 |
Technical Indicators
Market Signals| Indicator | APRE | SEGG |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 50.14 |
| Support Level | $0.74 | $0.70 |
| Resistance Level | $0.81 | $3.12 |
| Average True Range (ATR) | 0.06 | 0.36 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 23.68 | 13.73 |
Price Performance
Historical ComparisonAbout APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
About SEGG Lottery.com Inc.
Sports Entertainment Gaming Global Corp is a world-wide sports, entertainment and gaming company operating at the intersection of digital content, fan engagement and regulated gaming. It is building an integrated ecosystem designed to connect fans to the games, events and experiences it care about in compliant, technology-enabled environments. It is operated as a single-reporting unit focused on its lottery and gaming platform, and its organizational structure, internal reporting systems, and resource allocation processes were aligned accordingly. The company owns and operates three premium domain brands: Sports.com, Concerts.com, and Lottery.com representing the company's three operating focuses: Sports, Entertainment, and Gaming.